Galapagos NV (GLPGF)
| Market Cap | 2.16B |
| Revenue (ttm) | 323.67M |
| Net Income (ttm) | -333.85M |
| Shares Out | n/a |
| EPS (ttm) | -5.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 190 |
| Average Volume | 6 |
| Open | 26.20 |
| Previous Close | 33.45 |
| Day's Range | 26.20 - 33.45 |
| 52-Week Range | 22.39 - 33.45 |
| Beta | -0.05 |
| RSI | 99.98 |
| Earnings Date | Nov 5, 2025 |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Financial Performance
In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.
Financial numbers in EUR Financial StatementsNews
Galapagos appoints Aaron Cox as CFO
Galapagos Appoints Aaron Cox as Chief Financial Officer
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new...
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments
Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101
Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG stock prospects post Q1 earnings.
Galapagos NV outlines plans for pivotal CAR-T trials and SpinCo separation in 2025
Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal developme...
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outc...
Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shar...
Galapagos to Present at Upcoming Investor Conferences
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and in...
Disount To Net Cash For A Promising CAR-T Company
Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell ...
Galapagos receives transparency notification and 13D filing from Tang Capital
Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.
Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sri Ramaswami - Senior Vice President and Global Head of Corporate Affairs & Investor Rel...
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein
Galapagos To Spin Off Innovative Medicines Business
On January 8, 2025, Galapagos NV. (US Nasdaq ADR: GLPG; $23.76, Market Capitalization: $1.56 billion), announced its plans to split into two listed entities by mid-2025 by spinning off its activities ...
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, ...
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5...
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th Americ...
Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ET Company Participants Sofie Van Gijsel - Head of IR Paul Stoffels - Chair of the Board & CEO Thad Huston - CFO &...
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
Webcast presentation on October 31, 2024, at 1 3 :00 CET / 8:00 am ET, www.glpg.com
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director...